Table 2 Clinical data
Intervention group | N | Control group | N | p-value | |
|---|---|---|---|---|---|
Pre-measurement | |||||
MDS-UPDRS II (mean, SD) | 17.00 (6.23) | 15 | 15.06 (5.46) | 16 | 0.37 |
MDS-UPDRS III (mean, SD) | 38.50 (13.62) | 15 | 31.53 (11.98) | 16 | 0.146 |
Levodopa equivalent daily dose, mg (mean, SD) | 851.64 (391.54) | 19 | 900.88 (387.41) | 21 | 0.766 |
Motor fluctuations, on state (%) | 95 | 19 | 86 | 21 | |
Intake of other central nervous medication (%) | 47 | 19 | 43 | 21 | |
Post-measurement | |||||
MDS-UPDRS II (mean, SD) | 13.71 (5.27) | 15 | 12.53 (4.81) | 16 | 0.532 |
MDS-UPDRS III (mean, SD) | 28.36 (10.76) | 15 | 24.12 (8.45) | 16 | 0.242 |
Levodopa equivalent daily dose, mg (mean, SD) | 895.32 (474.09) | 19 | 885.98 (399.41) | 21 | 0.947 |
Motor fluctuations, on state (%) | 95 | 19 | 86 | 21 | |
Intake of other central nervous medication (%) | 47 | 19 | 57 | 21 | |